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Abstract
Background: To validate and update a prediction rule for estimating the risk of leprosy-related nerve function impairment
(NFI).
Methodology/Principal Findings: Prospective cohort using routinely collected data, in which we determined the
discriminative ability of a previously published rule and an updated rule with a concordance statistic (c). Additional risk
factors were analyzed with a Cox proportional hazards regression model. The population consisted of 1,037 leprosy patients
newly diagnosed between 2002 and 2003 in the health care facilities of the Rural Health Program in Nilphamari and
Rangpur districts in northwest Bangladesh. The primary outcome was the time until the start of treatment. An NFI event was
defined as the decision to treat NFI with corticosteroids after diagnosis. NFI occurred in 115 patients (13%; 95% confidence
interval 11%–16%). The original prediction rule had adequate discriminative ability (c=0.79), but could be improved by
substituting one predicting variable: ‘long-standing nerve function impairment at diagnosis’ by ‘anti-PGL-I antibodies’. The
adjusted prediction rule was slightly better (c=0.81) and identified more patients with NFI (80%) than the original
prediction rule (72%).
Conclusions/Significance: NFI can well be predicted by using the risk variables ‘leprosy classification’ and ‘anti-PGL-I
antibodies’. The use of these two variables that do not include NFI offer the possibility of predicting NFI, even before it
occurs for the first time. Surveillance beyond the treatment period can be targeted to those most likely to benefit from
preventing permanent disabilities.
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Introduction
Preventing permanent disabilities due to nerve function
impairment (NFI) [1] remains a major concern in leprosy control.
Mycobacterium leprae, the causative agent of leprosy, infiltrates
Schwann cells of peripheral nerve fibers [2]. Subsequently, the
nerve fibers can be damaged by accumulation of bacteria and
hypersensitivity reactions of the immune system. The decline of
nerve function can take place before, during and/or after leprosy
treatment. Early detection (within 6 months) and corticosteroid
treatment may prevent further decline [3]. With leprosy control
becoming less specialized and increasingly integrated into general
health care services, there is a need for simplified procedures at the
field level for timely identification and treatment of NFI in leprosy
patients. The chances of preventing disability increase when health
care workers pay special attention to patients who have a high risk
of developing NFI.
To date, several risk factors for NFI have been identified [4–6],
and an NFI prediction rule was formulated based on data from the
Bangladesh acute nerve damage study (Bands) [4]. The Bands
prediction rule categorizes patients into NFI risk groups based on
their World Health Organization (WHO) classification (ie,
paucibacillary [PB] or multibacillary [MB] leprosy) and the
presence of long-standing NFI at diagnosis. However, validation
of the Bands prediction rule is needed because i) the definition of
NFI has since changed; ii) shorter detection delays have led to a
smaller percentage of patients with NFI at diagnosis [7] which may
change the contribution of this variable to the prediction rule; iii) a
new and simple serological test for anti-phenolic glycolipid I (PGL-
I) antibody detection [8,9] has made routine screening feasible;
and iv) no study has simultaneously assessed all known potential
NFI risk factors, namely sex, age, WHO leprosy classification,
long-standing NFI at diagnosis, bacterial load and anti-PGL-I
antibodies [4–6].
www.plosntds.org 1 August 2008 | Volume 2 | Issue 8 | e283We first validated the Bands NFI prediction rule. Next, we
compared the performance of an adjusted NFI prediction rule,
taking presence of anti-PGL-I antibodies into account.
Methods
Patients and procedures
Patients were previously untreated leprosy patients, newly
diagnosed at the Rural Health Program (RHP) in northwest
Bangladesh in 2002 and 2003. All patients participated in the
Colep trial (ISRCTN 61223447) [10], which studied the effect of
chemoprophylaxis in persons who had contact with leprosy
patients (n patients=1,037). Patients were classified as PB or
MB according to the 1998 WHO classification [11] for treatment
purposes. For the current analysis, patients who had experienced
NFI for ,6 months at the time of diagnosis (n=162) were
excluded as they required immediate treatment with corticoste-
roids, which influences the future occurrence of NFI, the primary
outcome event of the study. Eleven patients were excluded because
essential data were missing. This leaves a study population of 864
patients (538 males, 326 females; median age 34 years, range 5–84
years). Follow-up ended in September 2006 (median follow-up
time 46 months). Patient information was prospectively recorded
on standardised forms by the RHP staff.
The primary outcome was the time until the start of treatment.
An NFI event was defined as the decision to treat NFI with
corticosteroids after diagnosis. The decision was based on the
guidelines described in the Rural Health Program (RHP, formerly
DBLM) treatment protocol, [12] which states that a full dose
course of prednisolone (starting with 40 mg/day and tapering off
over 16 weeks for adults) should be given in case of i) nerve
function reduction by $2 points in sensory and/or motor function
tests of the ulnar, median, and/or posterior tibial nerves; ii)
corneal anaesthesia; iii) a nerve tenderness score of 2; or iv) mixed
mild symptoms of neuritis (ie, tenderness, sensory, and motor
function scores of 1). The level of tenderness was defined as mild
(score=1) if palpation of the nerve causes some pain, but does not
cause the patient to jump or cry out and defined as severe
(score=2) if touching the nerve causes the patient to jump or cry
out. A low dose course of prednisolone (starting with 20 mg/day
and tapering off over eight weeks for adults) is given for i)
cutaneous neuritis; or ii) a mild skin reaction in a patch near or
overlying a facial nerve. Thus, the criteria to treat NFI with
prednisolone include all leprosy reactional and silent neuritis
events. In both the Bands and the current study, sensory testing
was performed with the Watson ball-point pen test, [13] motor
function was assessed according to Medical Research Council
grading [14], and changes in nerve function were evaluated by a
physiotechnician trained in nerve function assessment.
Patients were under monthly surveillance during standard
multidrug treatment (MDT): 6 months for PB patients, 12 months
for MB patients. In the original Bands study [4] recommendations
for extended surveillance were formulated, stating that for the low-
risk group—PB patients without long-standing NFI at diagnosis—
routinely performed surveillance for NFI during MDT is sufficient
and health education should be provided so that patients are able to
recognise and report NFI after completion of MDT. Medium-risk
group patients—PB patients with and MB patients without long-
standing NFI at diagnosis—require 12 months of surveillance and
health education, implying that extended surveillance is only
necessary for PB patients, who receive 6 months of MDT. For the
high-riskgroup—MBpatientswithlong-standingNFIatdiagnosis—
24monthsof surveillanceisrecommended,resulting in12 months of
surveillance in addition to the routine follow-up during MB MDT.
The bacterial load was determined by microscopy on Ziehl-
Neelsen stained slit skin smears [15] taken from the earlobe,
forehead and a skin lesion. The bacterial load was positive if any
bacteria were detected in one of the smears.
The presence of IgM antibodies against M. leprae was
determined at diagnosis with a previously described enzyme-
linked immunosorbent assay (ELISA), [16] using dried blood on
filter paper. Briefly, the terminal trisaccharide of phenolic
glycolipid I (PGL-I) linked to bovine serum albumin via a phenolic
ring (NT-P-BSA, kindly provided by Prof. T. Fujiwara, University
of Nara, Japan) was used as a semisynthetic analogue [17]. The
titer of IgM antibodies against M. leprae was expressed as net
optical density (OD): the absorbance of NT-P-BSA minus that of
BSA-coated wells at 450 nm. The status ‘‘seropositive’’ was
assigned if the net OD was $0.20.
Ethical implications
This study uses data and samples that are routinely collected by
the Rural Health Program from all leprosy patients before, during
and after treatment and when patients undergo leprosy reactions.
All patients included here gave written informed consent to
participate in the Colep trial (ISRCTN 61223447) [10], a study
approved by the Bangladesh Medical Research Council (BMRC/
ERC/2001-2004/799). By giving written informed consent to
participate in Colep and accepting treatment they agreed that
their data could be used anonymously for research.
Statistical analysis
Kaplan-Meier survival curves were used to determine the
cumulative incidence of NFI for the risk groups defined by the
prediction rules. Discriminative ability was expressed as a
concordance (c) statistic [18] (range 0.5–1.0). Cox proportional
hazards regression was used to identify independent variables that
influenced the hazard ratio for NFI. The results are expressed as
rate ratios or hazard ratios. Variables associated with NFI in
univariate analyses (p,0.10) were selected for multivariable
analysis in which stepwise backward selection was used to lessen
the number of predictors, inclusion at p,0.05. Interactions
between variables were tested but not included because they had
limited predictive effects. The total number of monthly surveil-
lances was calculated by multiplying the number in a risk group
with the recommended surveillance period. The formula for
Author Summary
Leprosy is caused by a bacterium that attacks the
peripheral nerves. This may cause nerve function impair-
ment (NFI), resulting in handicaps and disabilities. There-
fore, prediction and prevention of NFI is extremely
important in the management of leprosy. In 2000, a
prediction rule for NFI was published, but circumstances
have changed since the study was performed in the 1990s:
the leprosy detection delay has shortened and the
definition of NFI has changed. The original rule used
‘leprosy classification’ and ‘NFI present at diagnosis’ to
predict future NFI. In the current patient population we
studied an adjusted rule based on ‘leprosy classification’
and ‘presence of antibodies’. This adjusted rule predicted
NFI more often than the original rule. With the adjusted
rule it is now also possible to assess NFI risk before the first
nerve damage event takes place. This may help doctors
and health workers to improve surveillance for people at
high risk. Early detection and treatment can then prevent
permanent disabilities.
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surveillance based on the prediction rule the formula was (n low
risk*6)+(n medium risk*12)+(n high risk*24)]. The number of
surveillances needed to detect 1 case is the total number of
surveillances/NFI cases found. Data analyses were performed with
SPSS for Windows (version 14.0 SPSS Inc., Chicago, IL) and R
software (version 2.3.1 www.r-project.org).
Results
NFI occurred in 115 of 864 patients (13%; 95% confidence
interval [CI] 11–16%).
The Bands prediction rule defines NFI risk groups according to
the WHO leprosy classification (PB/MB) and longstanding NFI at
diagnosis. The low-risk group, comprised of PB patients without
longstanding NFI at diagnosis, had a cumulative NFI incidence of
4.0% (95% CI 2.8–5.9% [Figure 1]), the medium-risk group—PB
patients with and MB patients without longstanding NFI at
diagnosis—of 37% (95% CI 30–45%) and the high-risk group—
MB patients with longstanding NFI at diagnosis—of 53% (95% CI
40–68%). The cumulative incidences of NFI between the medium-
and high-risk groups did not differ significantly.
Substituting ‘long-standing NFI at diagnosis’ with ‘anti-PGL-I
antibodies’ resulted in risk groups with cumulative incidences
similar to those observed in the original Bands study (Figure 2) [4].
With the adjusted prediction rule the low-risk group—seronegative
PB patients—had a cumulative incidence of NFI of 3.5% (95% CI
2.2–5.4%), the medium-risk group—seropositive PB patients and
seronegative MB patients—of 13% (95% CI 8.5–19%), and the
high-risk group—seropositive MB patients—of 53% (95% CI 45–
62%). The cumulative incidences of NFI differed significantly
between low-, medium-, and high-risk groups. The cumulative
incidence of this medium-risk group is much lower than the 37%
in the medium-risk group defined by the Bands prediction rule.
Statistical analyses (Table 1) evaluated the association of NFI
with sex, age, WHO classification, long-standing NFI at diagnosis,
bacterial load, and anti-PGL-I antibodies. All variables but age
were univariately associated with NFI (p,0.05). A multivariable
analysis indicated that ‘WHO classification’ and ‘anti-PGL-I
antibodies’ were significantly associated with NFI (p,0.0001). MB
patients were at an increased risk of NFI (HR 8.0, 95% CI 5.0–
13.0) compared to PB patients, and seropositive patients had an
increased hazard risk of 2.9 (95% CI 1.8–4.6) compared to
seronegative patients. When adjusted for WHO classification, the
variables sex, age, bacterial load, and longstanding NFI at
diagnosis were not significantly associated with NFI anymore.
The observed c statistic for the Bands prediction rule in our
study was 0.79. The c statistic for the adjusted prediction rule was
0.81, showing a better discriminative ability. Table 2 shows the
number of patients that would be classified differently with the
adjusted prediction rule compared to the Bands prediction rule.
The adjusted prediction rule would place 115 of the low-risk group
patients in the medium-risk group and 97 of the medium-risk
group patients in the high-risk group; only 18 patients from the
medium-risk group and seven patients from the high-risk group
would be placed in a lower risk group.
Seventy-six (76/115, 66%) NFI events occurred while patients
were undergoing routine surveillance. For the remaining 39 NFI
events, additional surveillance would have been necessary for early
detection. Extended surveillance using the Bands prediction rule
[4] led to the detection of an additional seven patients with NFI for
a total of 83 (83/115, 72%: 726 extra visits needed). Using the
adjusted prediction rule, the number of additional detected
patients with NFI increased to 16, for a total of 92 (92/115,
80%: 2388 extra visits needed). With routine surveillance, 83.6
visits led to the detection of 1 case, for the Bands prediction rule
this was 85.3, and for the adjusted prediction rule 95.0.
Figure 1. Cumulative incidence of NFI for risk groups defined
by the Bands prediction rule, using WHO leprosy classification
and longstanding NFI at diagnosis as predictive variables.
NFI=nerve function impairment, Bands=Bangladesh acute nerve
damage study.
doi:10.1371/journal.pntd.0000283.g001
Figure 2. Cumulative incidence of NFI for risk groups defined
by the adjusted prediction rule, using WHO leprosy classifica-
tion and presence of anti-PGL-I antibodies as predictive
variables. NFI=nerve function impairment, PGL-I=phenolic glycolipid
I.
doi:10.1371/journal.pntd.0000283.g002
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Predicting NFI is important for identifying new leprosy patients
that are at risk for nerve damage and, consequently, permanent
disability. We describe an adjusted NFI prediction rule that
replaces the variable ‘longstanding NFI at diagnosis’ with ‘anti-
PGL-I antibodies’. The adjusted prediction rule was better able to
identify patients at risk of developing NFI after diagnosis.
The original Bands prediction rule for NFI is based on WHO
leprosy classification and long-standing NFI at diagnosis [4]. A
Kaplan-Meier survival analysis showed that the medium- and
high-risk groups had similar survival curves (Figure 1), indicating
that the Bands prediction rule could not differentiate between
these two groups. One explanation may be that the definition of
NFI has changed since the Bands study: a new NFI category, with
less serious events that require a low dose course of prednisolone,
was added to original NFI events that require a full dose course
[12]. This leads to more patients being identified at an early stage
of NFI. In addition, a smaller percentage of long-standing NFI (.6
months) and a higher percentage of recent NFI (,6 months), due
to shorter detection delays, may have changed the contribution of
longstanding NFI at diagnosis.
Presence of anti-PGL-I antibodies against M. leprae are a well-
known risk factor for NFI [5]. In-depth analysis of all known risk
factors for NFI in the current patient cohort showed that NFI is
best predicted by ‘WHO classification’ and ‘anti-PGL-I antibodies’
(Table 1). We adjusted the Bands prediction rule by replacing
‘long-standing NFI at diagnosis’ by ‘anti-PGL-I antibodies’. The
adjusted rule was able to differentiate between three risk groups
with significantly different cumulative incidences of NFI (Figure 2);
the c statistic increased from 0.79 to 0.81. Unfortunately, we could
not validate the adjusted prediction rule on the original Bands
cohort because no serology data were available.
The adjusted prediction rule distinguished three risk groups
comparable to those in the Bands study [4] (Figure 2). Therefore,
Table 1. Cox proportional hazards regression analysis, determination of NFI risk factors.
Variables Number NFI event Univariate Multivariable (full model) Multivariable (selected)
HR
a 95% CI HR
a 95% CI HR
a 95% CI
All patients 864 115
Sex
Male 538 87 1 1
Female 326 28 0.5 0.3–0.8 0.8 0.5–1.2
Age (years)
,15 136 11 0.6 0.3–1.2 0.7 0.3–1.3
15–29 294 39 1 1
30–39 161 25 1.2 0.7–2.0 1.1 0.6–1.8
$40 273 40 1.1 0.7–1.7 0.9 0.6–1.3
WHO leprosy classification
PB 669 29 1 1 1
MB 195 86 13.4 8.8–21 7.5 4.4–13.0 8.0 5.0–13.0
longstanding NFI at diagnosis
No 792 86 1 1
Yes 72 29 4.4 2.9–6.8 1.3 0.9–2.1
Bacterial load
b
Negative 759 66 1 1
Positive 91 48 8.2 5.7–12.0 1.0 0.6–1.6
Anti-PGL-I serology
Negative 605 31 1 1 1
Positive 259 84 7.5 5.0–11.3 2.7 1.6–4.5 2.9 1.8–4.6
aHR=hazard ratio.
bdata missing for 14 patients.
CI=confidence interval, NFI=nerve function impairment.
doi:10.1371/journal.pntd.0000283.t001
Table 2. Agreement between NFI risk groups according to
the Bands prediction rule and the adjusted prediction rule.
Bands rule Adjusted rule Total
Low risk Medium risk High risk
Low risk 531 (18) 115 (8) 0 646 (26) 4.0%
Medium risk 18 (1) 54 (13) 97 (49) 169 (63) 37.3%
High risk 0 7 (1) 42 (25) 49 (26) 53.1%
Total 549 (19) 3.5% 176 (22) 12.5% 139 (74) 53.2%
Table shows number of patients per risk group and (number of patients with
NFI event). Totals show number of patients, (number of patients with NFI event)
and percentage of NFI events in that particular group.
NFI=nerve function impairment, Bands=Bangladesh acute nerve damage
study.
doi:10.1371/journal.pntd.0000283.t002
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study [4] can be maintained (see Methods). When replacing the
Bands prediction rule with the adjusted prediction rule 212
patients were reassigned to a higher risk group and 25 patients to a
lower risk group (Table 2), suggesting that the adjusted prediction
rule has considerable implications for patient care. The reassign-
ment of these patients to a higher risk group is warranted because
they have a higher-than-average risk to develop NFI: 7% for
patients moving from the low to the medium risk group and 51%
for patients moving from the medium to the high risk group. The
adjusted prediction rule can thus be used to identify a substantially
higher number of new NFI cases than either routine or Bands rule-
based surveillance and offers increased opportunity to prevent
nerve damage in leprosy. However, the number of visits needed to
detect one case is higher than with alternative strategies. We
consider this operationally feasible and medically justifiable in view
of the serious consequences of NFI, including life-long disability.
WHO classification is a good predictor of future NFI [6] but it
rather crudely divides leprosy patients into two groups (PB and
MB). The presence of anti-PGL-I antibodies is known to correlate
with the bacterial load [16], and thus offers a further refinement of
the WHO classification into patients with high and low bacterial
loads. This may explain the added predictive value of the presence
of antibodies. In contrast to the Bands rule the adjusted rule uses
two variables that do not include NFI. This offers the possibility of
predicting NFI before it actually occurs.
We expect that the adjusted NFI prediction rule will be relevant
in other settings, since the predicting variables are well defined and
easily determined, but it should be validated externally. We believe
that the adjusted prediction rule can be applied in current health
services, since it fulfils the need for simplified guidelines and
diagnostic protocols. Contrary to the Bands prediction rule, the
adjusted rule does not rely on a specialist physiotechnician for the
prediction. However, this person is needed to document the
baseline nerve status and for surveillance during follow up
examinations. Recently, a simple anti-PGL-I field test was
developed that gives results within ten minutes, [8,9] making
routine testing feasible. Thus, leprosy diagnosis and NFI
prediction can be accomplished during a single consultation.
Additional benefits of the anti-PGL-I test are that it assists with the
classification and aids diagnosis of leprosy patients with doubtful
clinical signs [8,9,16].
With the adjusted prediction rule, the necessity to continue
surveillance beyond the treatment period can be determined. New
leprosy patients can be assigned to an NFI risk group, and
appropriate surveillance can be planned. Nerve damage can thus
be successfully prevented despite the fact that leprosy control has
been integrated into general health services.
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